KEYTRUDA Combo Shows Long-Term Gains in Uterine Cancer

In patients with advanced endometrial cancer, five-year data from the Phase 3 KEYNOTE-775/Study 309 trial revealed a durable survival benefit for KEYTRUDA plus LENVIMA compared to chemotherapy, according to Merck, which is known as MSD outside of the US and Canada, and Eisai.

These results were reported at the 2025 Congress of the European Society of Medical Oncology (ESMO).

The investigation showed that the combo therapy continued to improve overall survival over a five-year period, with no new safety issues noted. 827 patients with advanced endometrial cancer who had previously undergone platinum-based chemotherapy were recruited for this experiment.

Also Read: QR Code Soon Mandatory on Vaccines, Anticancer and Narcotic Drugs

“Endometrial carcinoma remains challenging to treat in the recurrent or advanced setting, particularly for patients with mismatch repair proficient tumors, which are less responsive to immunotherapy alone,” said Dr. Vicky Makker, Principal Investigator and Gynecologic Medical Oncologist at Memorial Sloan Kettering Cancer Center.

“These five-year data from KEYNOTE-775/Study 309 demonstrate a sustained survival benefit with pembrolizumab plus lenvatinib, underscoring the combination’s important role as an effective treatment options for this patient population.” “Recent advances have driven meaningful progress for patients with advanced endometrial carcinoma,” said Dr. Gregory Lubiniecki, Vice President, Global Clinical Development, Merck Research Laboratories.

“The five-year results reinforce the durable survival benefit of KEYTRUDA plus LENVIMA and highlight our ongoing commitment to improving outcomes for patients with women’s cancers.”